The anti-inflammatory effects of nebivolol in human coronary smooth muscle cells: Clinical implications

International Journal of Cardiology

Volumn 133, Issue 3, 2009, Pages 415-416

  Celik, Turgay ^a   Iyisoy, Atila ^a   Kardesoglu, Ejder ^b   Fici, Francesco ^c  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b GATA HAYDARPASA TRAINING HOSPITAL   (Turkey)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Atherosclerosis; Nebivolol; Pleitropic effects; Vascular inflammation

Indexed keywords

ADIPONECTIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; METOPROLOL SUCCINATE; NEBIVOLOL; PADGEM PROTEIN; BENZOPYRAN DERIVATIVE; ETHANOLAMINE DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT;

ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD PRESSURE; CELL PROLIFERATION; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; HEART ATRIUM FIBRILLATION; HEART MUSCLE CELL; HEART RATE; HUMAN; HYPERTENSION; INSULIN RESISTANCE; OXIDATIVE STRESS; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; CORONARY BLOOD VESSEL; DRUG EFFECTS; PATHOPHYSIOLOGY; PHYSIOLOGY; VASCULAR SMOOTH MUSCLE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BENZOPYRANS; CORONARY VESSELS; ETHANOLAMINES; HUMANS; HYPERTENSION; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE;

EID: 63149124997     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2007.11.095     Document Type: Article

References (8)

1. Wolf S.C., Sauter G., Jobst J., Kempf V.A., Risler T., and Brehm B.R. Major differences in gene expression in human coronary smooth muscle cells after nebivolol or metoprolol treatment. Int J Cardiol 125 (2008) 4-10
2. de Boer R.A., Voors A.A., and van Veldhuisen D.J. Nebivolol: third-generation beta-blockade. Expert Opin Pharmacother 8 (2007) 1539-1550
3. Agabiti Rosei E., and Rizzoni D. Metabolic profile of nebivolol, a beta-adrenoceptor antagonist with unique characteristics. Drugs 67 (2007) 1097-1107
4. Celik T., Iyisoy A., Kursaklioglu H., et al. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertens 24 (2006) 591-596
5. Korantzopoulos P., Kolettis T.M., Galaris D., and Goudevenos J.A. The role of oxidative stress in the pathogenesis and perpetuation of atrial fibrillation. Int J Cardiol 115 (Feb 7 2007) 135-143
6. Acikel S., Bozbas H., Gultekin B., et al. Comparison of the efficacy of metoprolol and carvedilol for preventing atrial fibrillation after coronary bypass surgery. Int J Cardiol 126 (2008) 108-113
7. Cioffi G., De Feo S., Pulignano G., et al. Does atrial fibrillation in very elderly patients with chronic systolic heart failure limit the use of carvedilol?. Int J Cardiol 107 (Feb 15 2006) 220-224
8. Bangalore S., Messerli F.H., Kostis J.B., and Pepine C.J. Cardiovascular protection using beta-blockers: a critical review of the evidence. J Am Coll Cardiol 50 (2007) 563-572